Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.36 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127361 | 0.86 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11738023 | 0.82 | DNM1 (0.50) | TSHRALDH1A1DNM1 | |
| SCHEMBL18163782 | 0.77 | — | — | |
| SCHEMBL11753890 | 0.69 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15091 | 0.69 | CA12 (0.52) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31371032 | 0.68 | CHRNB2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12918862 | 0.67 | CA12 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL473385 | 0.67 | CA12 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL174185 | 0.67 | — | — | |
| SCHEMBL3973874 | 0.67 | CA12 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0148637-B1 | IMPROVED SURFACE COATING COMPOSITIONS | ALCAN INTERNATIONAL LIMITED (CA) | 1986-11-26 | — | — | EP | claimed |
| EP-0148637-A1 | Improved surface coating compositions | ALCAN INTERNATIONAL LIMITED (CA) | 1985-07-17 | — | — | EP | claimed |
| EP-2429957-B1 | TAGGED SCALE INHIBITORS | ABSOLUTE PETRO HYDRO TECH CO LTD (CN) | 2015-07-29 | — | — | EP | disclosed |
| EP-2429957-A1 | TAGGED SCALE INHIBITORS | Absolute Petro Hydro Tech Co. Ltd (CN) | 2012-03-21 | — | — | EP | disclosed |
| US-20120048808-A1 | TAGGED SCALE INHIBITORS | ABSOLUTE PETRO HYDRO TECH CO. LTD (CN) | 2012-03-01 | — | — | US | disclosed |
| US-7888417-B2 | core or the layer includes a composition formed from a base polymer, a crosslink initiator, and at least one additive; additive has at least one carbon-oxygen-boron linkage, carbon in the linkage being a secondary or tertiary carbon; enhances coefficient of restitution and/or reduces compression of core | ACUSHNET COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2010128322-A1 | TAGGED SCALE INHIBITORS | ABSOLUTE PETRO HYDRO TECH CO. LTD (CN) | 2010-11-11 | — | — | WO | disclosed |
| US-7820810-B2 | Process for the synthesis of 2′-O-substituted purine nulceosides | ISIS PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080261722-A1 | COMPOSITIONS FOR USE IN GOLF BALLS | ACUSHNET COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080234475-A1 | PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PURINES | IONIS PHARMACEUTICALS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080227567-A1 | COMPOSITIONS FOR USE IN GOLF BALLS | ACUSHNET COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20060281586-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2006-12-14 | — | — | US | disclosed |
| US-20060281587-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2006-12-14 | — | — | US | disclosed |
| US-20050245657-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| US-20050245652-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| US-4631087-A | ALUMINUM ALKOXIDE, ORGANIC BASE WITH AMMONDA STABILIZER; COPPER, MANGANESE, COBALT, OR ZINC ORGANIC COMPOUND | ALCAN INTERNATIONAL LIMITED (CA) | 1986-12-23 | — | — | US | disclosed |
| EP-0148636-B1 | IMPROVED SURFACE COATING COMPOSITIONS | ALCAN INTERNATIONAL LIMITED (CA) | 1986-11-26 | — | — | EP | disclosed |
| EP-0148637-B1 | IMPROVED SURFACE COATING COMPOSITIONS | ALCAN INTERNATIONAL LIMITED (CA) | 1986-11-26 | — | — | EP | disclosed |
| EP-0148637-A1 | Improved surface coating compositions | ALCAN INTERNATIONAL LIMITED (CA) | 1985-07-17 | — | — | EP | disclosed |
| EP-0148636-A2 | Improved surface coating compositions | ALCAN INTERNATIONAL LIMITED (CA) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234475-A1 | PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PURINES | PNP, NUDT1, UMPS | CHRM2 4560/4885CHRM4 3795/4885CHRM5 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.